脑转移瘤治疗方法的选择和疗效分析
|
摘要
目的研究分析脑转移瘤治疗更适合的治疗方案。方法将我们所在医院2016年03月至2018年03月接收的117例脑转移瘤患者作为研究对象,根据其治疗方案的不同分为Ⅰ、Ⅱ、Ⅲ组,每组39例。研究分析Ⅰ、Ⅱ、Ⅲ组患者治疗后的治疗效果和生存率。结果Ⅱ、Ⅲ组的患者治疗后6、12、18个月的治疗效果和生存率均显著高于Ⅰ组,Ⅲ组患者治疗后12、18个月治疗效果和生存率显著高于Ⅱ组,差异显著(P<0.05)。结论WBRT+SRT+化疗的治疗方案能够有效提高脑转移癌患者的治疗效果和生存率,是脑转移瘤更适合的治疗方案,值得临床推广。
Objective To study the treatment of brain metastases for a more suitable treatment. Methods A total of 117 patients with brain metastases who were admitted to our hospital from March 2016 to March 2018 were enrolled in the study. They were divided into groups I, II and III according to their treatment options, with 39 cases in each group. To study the therapeutic effects and survival rate of patients in groups I, II and III after treatment. Results The treatment and survival rate of patients in group II and III were significantly higher than those in group I at 6, 12, and 18 months after treatment. The treatment effect and survival rate of group III patients at 12 and 18 months after treatment were significantly higher than those in group II. The difference was significant(P<0.05). Conclusion WBRT+SRT+chemotherapy can effectively improve the therapeutic effect and survival rate of patients with brain metastases. It is a more suitable treatment plan for brain metastases and it is worthy of clinical promotion.
Objective To study the treatment of brain metastases for a more suitable treatment. Methods A total of 117 patients with brain metastases who were admitted to our hospital from March 2016 to March 2018 were enrolled in the study. They were divided into groups I, II and III according to their treatment options, with 39 cases in each group. To study the therapeutic effects and survival rate of patients in groups I, II and III after treatment. Results The treatment and survival rate of patients in group II and III were significantly higher than those in group I at 6, 12, and 18 months after treatment. The treatment effect and survival rate of group III patients at 12 and 18 months after treatment were significantly higher than those in group II. The difference was significant(P<0.05). Conclusion WBRT+SRT+chemotherapy can effectively improve the therapeutic effect and survival rate of patients with brain metastases. It is a more suitable treatment plan for brain metastases and it is worthy of clinical promotion.
引文
[1]王建峰,刘花利,孟喜君.SRS、WBRT及WBRT+SRS治疗1-4个脑转移瘤的Meta分析[J].现代肿瘤医学,2016,24(15):2443-2448.
[2]张春满,郑云峰,米娟.立体定向放射治疗和全脑放射治疗脑转移瘤对患者神经认知功能和健康相关生活质量的影响分析[J].临床和实验医学杂志,2016,15(15):1514-1517.
[3]孙迪,张盛,林光勇,等.厄洛替尼同步WBRT对EGFR突变阳性肺腺癌多发脑转移的临床疗效[J].中华放射肿瘤学杂志,2018,32(5):463-466.
[4]刘莲花,杨晓峰,贺方学,等.肺癌脑转移瘤放疗方案比较临床疗效及预后分析[J].中华肿瘤防治杂志,2014,21(2):143-146.
[5]张国荣,郁志龙,刘秀兰.肺癌脑转移瘤不同放射治疗方法的疗效分析[J].内蒙古医学杂志,2014,46(06):651-654.
[6]孙红梅,陈文彰,燕丽香,等.非小细胞肺癌脑转移瘤不同治疗方法的疗效评价以及预后分析[J].现代肿瘤医学,2013,21(03):568-572.
[2]张春满,郑云峰,米娟.立体定向放射治疗和全脑放射治疗脑转移瘤对患者神经认知功能和健康相关生活质量的影响分析[J].临床和实验医学杂志,2016,15(15):1514-1517.
[3]孙迪,张盛,林光勇,等.厄洛替尼同步WBRT对EGFR突变阳性肺腺癌多发脑转移的临床疗效[J].中华放射肿瘤学杂志,2018,32(5):463-466.
[4]刘莲花,杨晓峰,贺方学,等.肺癌脑转移瘤放疗方案比较临床疗效及预后分析[J].中华肿瘤防治杂志,2014,21(2):143-146.
[5]张国荣,郁志龙,刘秀兰.肺癌脑转移瘤不同放射治疗方法的疗效分析[J].内蒙古医学杂志,2014,46(06):651-654.
[6]孙红梅,陈文彰,燕丽香,等.非小细胞肺癌脑转移瘤不同治疗方法的疗效评价以及预后分析[J].现代肿瘤医学,2013,21(03):568-572.